Introduction
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer-related death globally. 1, 2 Despite great advances in early diagnosis and treatments, the prognosis, especially the long-term survival, remains dissatisfactory in patients with HCC. [3] [4] [5] [6] Additionally, the prognostic markers of HCC have not been completely elucidated. Established prognostic factors can contribute to predicting the survival and relapse for HCC patients as well as guiding their clinical management.
Recently, several serum markers that can be used as noninvasive tools have been identified in human cancers, including HCC. [7] [8] [9] [10] Among them, there has been great interest in the aspartate aminotransferase-to-platelet ratio index (APRI) because it is an inexpensive and feasible test that can be used for daily oncologic practice.
It has been reported that APRI might be a candidate as a prognostic biomarker in HCC. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] However, there were shortcomings in the current clinical studies because they were of limited sample sizes, and some results regarding the clinical value of
Data extraction and quality assessment
The collected information from all studies included name of the first author, study country, year of publication, included time, sample size, number of male and female patients, age distribution, survival type, follow-up period, cutoff value for APRI, cutoff selection, treatment methods, tumor stage, HR, and the corresponding 95% CI. HRs and the corresponding 95% CIs were directly extracted from the original article if a study reported the HRs and 95% CIs in univariate and/or multivariate analysis. Otherwise, Engauge Digitizer software (version 4.1) was used to estimate the HR from the Kaplan-Meier curve.
All included studies were assessed by the NewcastleOttawa quality assessment scale (NOS). In this method, NOS scores ranged from 0 (lowest) to 9 (highest) points. A study with an NOS score ≥6 was considered to be of high quality.
statistical analysis
In this meta-analysis, statistical analyses for pooled HRs were executed using Stata 12.0 software (Stata, College Station, TX, USA).
For measuring the heterogeneity among research studies, Cochran's Q test and Higgins I-squared statistic were applied. A probability value of P Q <0.05 or I 2 >50%indicated that heterogeneity existed. If heterogeneity was present, the random-effects model was used to calculate the integrated HRs. If there was no significant heterogeneity across studies, the fixed-effects model was adopted.
Funnel plot and Begg's test were used to judge the potential publication bias. Sensitivity analysis was applied to evaluate the robustness of the pooled results. All P-values <0.05 were regarded as statistically significant.
Results
The detailed steps of the potential literature search are shown in Figure 1 . Based on the selection criteria for the eligible studies, high-quality articles (including 17 studies) written in English were identified in this meta-analysis. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] A total of 5,051 patients with HCC were enrolled. All included studies were retrospective and reported the relationship between the APRI value and HCC prognosis. The detailed characteristics of all included studies are summarized in Table 1 .
Relationship between aPRi and overall survival in hCC
A total of 12 articles (including 14 studies) with 4,558 subjects reported the relationship between APRI and overall survival (OS) in patients with HCC. Considering the significant heterogeneity among these articles (I 2 =62.9%, P Q =0.001), a random-effects model was applied. As shown in Figure 2 , the overall results indicated that elevated APRI predicted a poor outcome for OS of HCC (HR =1.62, 95% CI: 1.23-2.01).
Exploratory subgroup analyses were performed according to analysis type (multivariate analysis and univariate analysis), cutoff value selection (receiver operating characteristic curve and Others), and treatments (With surgery, No surgery, and Mixed). Table 2 shows that the calculated pooled HR values were significantly >1.0 in those subgroup analyses. Interestingly, the APRI could be an independent predictor of OS in patients with HCC (HR =1.41, 95% CI: 1.08-1.73, P<0.001).
Nine studies with a total of 2,965 HCC patients reported the prognostic value of APRI for recurrence-free survival (RFS). No significant heterogeneity was observed among studies (I 2 =0.0%, P Q =0.930), and the fixed-effects model was adopted. The pooled HR was 1.83 (95% CI: 1.48-2.18, P<0.001; Figure 3 ), indicating that high APRI was an unfavorable factor for RFS in HCC. In addition, we found that the analysis types, cutoff value selections, and treatments did not affect the prognostic predictor of RFS in HCC patients from the subgroup analyses (Table 3) . Records excluded (n=155)
Additional records identified through other sources (n=0) Figure 1 The flowchart of literature selection. Five studies, consisting of 1,677 patients, explored the association between APRI and disease-free survival (DFS) in multivariate analysis. There was no obvious heterogeneity across studies (I 2 =0.0%, P Q =0.814), and therefore, the fixedeffects model was used. Analysis revealed the pooled HR of 1.46 with 95% CI: 1.26-1.66 (P<0.001), which showed that APRI was an independent predictive factor of DFS in patients with HCC (Figure 4 ).
Publication bias
Funnel plot and Begg's test both suggested no evidence of publication bias for OS, RFS, and DFS (Pr Begg's test >|z|=0.228 for OS; Pr Begg's test >|z|=0.118 for RFS; Pr Begg's test >|z|=1.000 for DFS; Figure 5 ).
sensitivity analysis
Sensitivity analysis was performed to assess the potential impact of each individual study on the overall results. The results showed that any single study had little influence on the pooled results ( Figure 6 ), thus indicating that our results were relatively stable and credible.
Discussion
As a noninvasive scoring marker, APRI consists of two routinely available clinical and laboratory variables, aspartate aminotransferase (AST) and platelets (PLT), and can be calculated using the following formula: (AST / the upper limit of normal value)×100: PLT (10 9 /L). 26 It was firstly proposed as a simple, straightforward test to assess liver fibrosis stage and liver function reserve. [27] [28] [29] In-depth studies determined that APRI also had potential prognostic value and could be used as a stable marker to predict the outcome of patients with HCC. [11] [12] [13] It has been known that AST and PLT play an important role in tumor progression and are associated with prognosis in several human cancers, including HCC. 15, 30, 31 APRI is a combination of the above two predictors, and it is low in cost and more easily detectable. Its clinical predictive value could be enhanced due to its stability and reliability. 
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The exact mechanisms governing the prognostic values of APRI still remain unclear; however, there are some possible explanations. 24, 25 HCC patients with a high APRI value frequently have elevated AST levels, and the level of AST could represent the cirrhosis level or the injury to the hepatocytes, and could also reflect liver stress or damage arising from progressive liver fibrosis or reactivation of hepatitis virus replication. All of these are major contributors to liver carcinogenesis. [32] [33] [34] In contrast, many patients with HCC and elevated APRI often have a low PLT level. Progressive destruction of an enlarged spleen and progressive liver fibrosis can often lead to low preoperative PLT, [35] [36] [37] and there were also close relationships between low preoperative PLT and great risk of major liver-related complications. 37, 38 All of these factors and events are closely linked to poor clinical outcomes in HCC patients. Figure 3 Forest plot for the relationship between aPRi and RFs. Abbreviations: aPRi, aminotransferase-to-platelet ratio index; hR, hazard ratio; RFs, recurrence-free survival. To the best of our knowledge, this is the first meta-analysis that comprehensively assesses the prognostic value of APRI in HCC. In the present meta-analysis, a total of 15 published articles with 5,051 HCC patients were collected. When the outcomes from all available studies were combined and pooled, we found that an elevated APRI was significantly associated with poor OS (HR =1.62, 95% CI: 1.23-2.01) in HCC, although there was heterogeneity. Furthermore, the subgroup analyses Nevertheless, there are some limitations existing in the meta-analysis that should be carefully interpreted. Firstly, all studies enrolled were retrospective, and the number of published studies included was not sufficiently large for a more detailed subgroup analysis. Secondly, because the majority of studies included were from Asian countries (China, Japan, and Korea), additional clinical studies from other countries are required. Thirdly, four of 14 studies for OS only reported HRs in the univariate analysis, which might cause a bias toward overestimation of the prognostic role of APRI. In addition, some heterogeneity was observed among studies for OS, which was probably due to factors such as the adjusted multivariate analysis of studies with different factors or different start time to follow-up or diverse therapies applied. In addition, there are some other factors that could influence AST and PLT, such as antiviral drugs and other accompanying diseases of the patients, and this should also be noted. Finally, the cutoff value for defining high or low APRI differed in studies, and it is essential that they be unified before APRI can be utilized in clinical prognostication for HCC.
In summary, the results of our study suggest that high APRI indicated poor prognosis in HCC patients, and APRI could serve as a cost-effective, significant biomarker for predicting HCC survival outcome. Considering the limitations mentioned Tang T-2, et al 2018 25 Tang T-1, et al 2018 25 Huang HH, et al 2010 11 Meta-analysis estimates, given named study is omitted Lower CI Pang Q-2, et al 2015 14 Teng W, et al 2017 21 Sarkar J, et al 2017 23 Toyoda H, et al 2017 22 Yang HJ, et al 2017 24 Ji F, et al 2016 18 Peng W, et al 2016 20 Shen SL, et al 2014 13 Huang HH, et al 2010 11 Toyoda H, et al 2017 22 Chuang HA, et al 2016 17 Teng W, et al 2017 21 Liu Y, et al 2016 19 Pang Q, et al 2015 15 Okamura Y, et al 2016 16 Kao W, et al 2011 12 Peng W, et al 2016 20 Ji F, et al 2016 18 Yang HJ, et al 2017 24 Pang Q-1, et al 2015 14 Pang Q-2, et al 2015 14 Shen SL, et al 2014 
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aPRi: a promising prognostic biomarker in hCC above, larger well-designed clinical studies with more diverse populations are warranted in the future to validate our findings.
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